Abstract 1501P
Background
The Gender differences in the clinical symptoms presentation (CSP) are known and already studied in many settings of medicine, such as Cardiology and Neurology. However, these differences have been studied less deeply in Oncology and Palliative Care. Our analysis focused on evluating how gender can affect the CSP in an integrated outpatient clinic between Radiotherapy and Palliative Care (RaP).
Methods
This is a monocentric, observational study carried out in the RaP integrated outpatient clinic in a Research Cancer Hospital (IRCCS, IRST - Meldola, Italy). Descriptive statistics were reported for each Edmonton Symptom Assessment System (ESAS) item, separately by gender. Additionally, a set of linear models were developed to predict ESAS items score. Multivariable linear model incorporated all other symptoms, clinical characteristics (e.g tumor location), and the sex variable to evaluate possible gender effects. All analyses were performed using R statistical software.
Results
212 patients were enrolled in the study between 2016 and 2020. Most of the symptoms showed significant gender differences. Specifically, the symptom "Pain” showed higer values in the male population (mean: M5.1 vs. F 4.4). Conversely, the symptom "Anxiety” showed higer values in the female population (mean. M 2.0 vs F 3.0). Finally, the "total symptom distress score” resulted in higer values in the female population (mean: M 23.0 vs F 25.4). Interestingly, the symptom "malaise” is the only that showed an almost perfect equity for all values (mean M1.9 vs F 2.0). The linear model aimed at assessing, ceteris paribus, report 0.9 additional points than females (p= 0.053). Conversely, keeping constant all other factors, females report 0.95 higer expression of anxiety (p=0.002).
Conclusions
The gender differences in the CSP and their distribution highligheted in our analysis are important in the new subfield of medicine called "Gender Medicine". Especially in palliative care, data relating to patients symptoms is necessary to reach the goal of the best supoportive care. Additional studeis will be necessary to improve our knowledge in this field.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
L. Tontini.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1564P - Limited participation in breast cancer screening among low-SES women: A matter of engagement or of health literacy?
Presenter: Allegra Ferrari
Session: Poster session 10
1566P - Optimizing participation in lung cancer screening program: Results from the first round in ILYAD study in Lyon University Hospital
Presenter: Emmanuel Grolleau
Session: Poster session 10
1567P - Physicians' adenoma detection rate and the risk of colorectal cancer in sequential screening programs: An observational cohort study
Presenter: Li Xie
Session: Poster session 10
1568P - Challenges in pilot lung cancer screening in Vojvodina, Serbia
Presenter: Jelena Djekic Malbasa
Session: Poster session 10
1569P - Secondary delay in breast cancer diagnosis and role of rural medical practitioners: A cause and cure finding study
Presenter: Rahul Agarwal
Session: Poster session 10
1570P - Factors and impacts of delayed presentation for county-level patients with breast cancer in a real-life setting in China
Presenter: Yinghua Ji
Session: Poster session 10
1571P - The reasons that motivate a change of specialties among oncology residents
Presenter: Christophe Ducrocq
Session: Poster session 10
1572P - Factors associated with career choice in oncology among medical students
Presenter: Nicolas Penel
Session: Poster session 10
1573P - Global cancer statistics for adolescents and young adults: New estimates from GLOBOCAN 2022
Presenter: Wang-Zhong Li
Session: Poster session 10
Resources:
Abstract